Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

Cobenfy doesn’t have the same severe side effects as older schizophrenia medications — like weight gain, involuntary muscle ...

Discover the potential of GLP-1 medications like Ozempic and Mounjaro in treating a wide range of conditions, from diabetes to addiction.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab ...

In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

After a delay, the FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...

The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.